All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Crohn's disease (CD) and ulcerative colitis (UC) are the principal types of inflammatory bowel diseases (IBDs) \[[@pone.0145087.ref001],[@pone.0145087.ref002]\]. IBDs, which are chronic diseases, are characterized by inflammation of the mucosal lining of the gastrointestinal tract. Their worldwide incidence has increased during the last decade, but the annual incidence and prevalence of CD and UC are the highest in Northern Europe and in North America \[[@pone.0145087.ref003]\]. The incidence of CD is 12.7 per 100,000 person-years in Europe and 20.2 person-years in North America, while the incidence of UC is 24.3 in Europe and 19.2 in North America. Unemployment, sick leave, and permanent work disability are more commonly associated with patients with IBD than with the general population \[[@pone.0145087.ref004]\]. IBDs affect mainly young adults, causing an even greater economic burden.

Treatment of IBDs is aimed at relieving the symptoms and complications of IBDs as well as preventing recurrence and improving the patient's quality of life \[[@pone.0145087.ref005],[@pone.0145087.ref006]\]. IBD patients usually require lifelong medical treatment. Both CD and UC are treated with conventional medical treatment comprising corticosteroids, aminosalicylates, and immunomodulators (e.g., azathioprine, 6-mercaptopurine, and methotrexate). Other treatment options include surgery and diet therapy \[[@pone.0145087.ref005]--[@pone.0145087.ref007]\]. Biologic drugs based on two different mechanisms of action are currently available for the treatment of IBDs \[[@pone.0145087.ref008]\]. Infliximab (IFX), adalimumab (ADA), golimumab, and certolizumab pegol (CTZ) are tumor necrosis factor (TNF) inhibitors while natalizumab (NTZ) and vedolizumab target the α4-integrin \[[@pone.0145087.ref009],[@pone.0145087.ref010]\]. Biologics are used to treat IBD refractory to corticosteroids or immunomodulators or IBD patients who are steroid-dependent or steroid-intolerant \[[@pone.0145087.ref005],[@pone.0145087.ref006]\]. However, biologics are significantly more expensive than conventional drugs \[[@pone.0145087.ref011],[@pone.0145087.ref012]\]. The introduction of TNF inhibitors has changed the cost profile of healthcare costs of IBDs \[[@pone.0145087.ref012],[@pone.0145087.ref013]\]. Nowadays the main source of costs is drugs, especially TNF inhibitors, while earlier the healthcare costs were mainly driven by the hospitalization and the surgery. Biologics have been shown to be effective in inducing and maintaining remission of IBD \[[@pone.0145087.ref005],[@pone.0145087.ref006],[@pone.0145087.ref008],[@pone.0145087.ref014]--[@pone.0145087.ref016]\]. Despite their proven efficacy, treatment failures may manifest as primary non-response, secondary loss of response, or failure of re-induction therapy \[[@pone.0145087.ref005],[@pone.0145087.ref006],[@pone.0145087.ref017]\]. Patients who fail to respond to TNF inhibitor may benefit from biologic drug with a different mechanism of action, while an alternative TNF inhibitor may be an effective treatment strategy in case of loss of response over time. The evidence on the cost-effectiveness of biologics for the treatment of IBD is limited, and the results of previous systematic reviews are inconsistent and incomplete \[[@pone.0145087.ref018]--[@pone.0145087.ref022]\].

The field of cost-effectiveness analysis (CEA) involves the comparison of health interventions based on both costs and effectiveness \[[@pone.0145087.ref023],[@pone.0145087.ref024]\]. Cost-utility analysis (CUA) is a type of CEA. The outcome measure of the CUA is the incremental cost-effectiveness ratio (ICER), representing the difference in costs between two alternatives divided by the difference in effectiveness between the same two alternatives. An intervention dominates another if its effectiveness is higher and its costs are lower \[[@pone.0145087.ref024]\]. While the health effects are measured in natural units in the CEA, the measure of consequences in the CUA is the Quality-Adjusted Life Year (QALY) \[[@pone.0145087.ref024],[@pone.0145087.ref025]\]. The QALY takes into account both the quantity and quality of life and can be measured by either direct or indirect methods. Costs are classified as direct and indirect costs \[[@pone.0145087.ref024],[@pone.0145087.ref026]\]. Direct costs denote the resources consumed, while indirect costs are costs due to the loss of productivity related to illness or death. CEA can be conducted using an empirical, observational, or modeling approach \[[@pone.0145087.ref024]\]. The modeling study appears to be the most common type of CEA, combining clinical data and cost data from many sources. Modeling studies can be tested by sensitivity analysis.

The CEAs provide valuable information for health care decision-makers and enable efficient spending \[[@pone.0145087.ref024]\]. The aim of this systematic review is to evaluate existing relevant evidence regarding the cost-effectiveness of biologics for the treatment of IBDs. The cost-effectiveness of biologics is compared with placebo treatment, conventional medical treatment, surgery, and another biologic treatment for adults with diagnosed IBD. The aim of this review is also to analyze the source of effectiveness of CEAs. Furthermore, this review assesses the quality of the included CEAs using three different quality assessment checklists.

Materials and Methods {#sec006}
=====================

Literature Search {#sec007}
-----------------

A comprehensive literature search on the cost-effectiveness of biologics for the treatment of IBDs was performed using Medline (Ovid), Cochrane Library (Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, Cochrane Central Register of Controlled Trials, Cochrane Methodology Register, Heath Technology Assessment Database, and NHS Economic Evaluation Database), and SCOPUS (including Embase) in June 2014. The search strategies were developed together with an information specialist. The reference lists of relevant articles were scrutinized. Furthermore, the grey literature and other relevant websites and databases (Centre for Reviews and Dissemination, Current Controlled Trials, Clinical Trials.gov, and PROSPERO) were hand-searched for relevant studies.

The electronic search strategy was based on patients (IBD, CD, or UC), intervention (biologics), and outcomes (ICER) in different spellings ([S1 File](#pone.0145087.s001){ref-type="supplementary-material"}). The biologics granted a marketing authorization by the European Medicines Agency (EMA) or US Food and Drug Administration (FDA) before May 2014 were included in the literature search strategy \[[@pone.0145087.ref009],[@pone.0145087.ref010]\]. No restriction was set based on the year of the publication.

Study Selection {#sec008}
---------------

The study selection was based on the inclusion and the exclusion criteria formulated by the framework of PICOTS i.e., population, intervention, comparator, outcome, timing, and setting ([S1 Table](#pone.0145087.s003){ref-type="supplementary-material"}) \[[@pone.0145087.ref027]\]. The study selection procedure encompassed three main stages. At the first stage, hits from the electronic databases were imported into reference management software (RefWorks). After removing duplicate citations, the second stage focused on the evaluation of the remaining studies based on their titles and abstracts. Studies clearly indicated as irrelevant to the study subject were excluded. The full articles retrieved that met the inclusion criteria are included in the current review. The identified abstracts and full texts were screened for eligibility by one reviewer (SH) and the second reviewer (MB) was consulted.

Data Extraction {#sec009}
---------------

Our data extraction form was based on the Cochrane Handbook for Systematic Reviews of Intervention and the abstract form of the NHS Economic Evaluation Database \[[@pone.0145087.ref028],[@pone.0145087.ref029]\]. The following items were extracted: patients, interventions, controls, study design (the type of economic evaluation and modeling, perspective, time horizon, country, included costs, the methods of measuring and valuing outcomes and benefits, discount rate, currency, price year, and the type of sensitivity analysis) and outcomes (total costs and benefits, ICER, and the results of sensitivity analysis). In order to facilitate the comparison of estimates collected from different studies, all costs were converted to 2014 euro using the exchange rates of the European Central Bank and the value of money index published by Statistics Finland \[[@pone.0145087.ref030],[@pone.0145087.ref031]\]. Data were extracted using Microsoft Excel and performed by one assessor (SH) and ambiguities were solved by another assessor (MB) for accuracy.

Quality Assessment {#sec010}
------------------

The methodological quality of the studies was assessed using three standardized checklists. All studies were assessed using Drummond's checklist, published by the British Medical Journal Working Party, and the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) guidelines \[[@pone.0145087.ref032],[@pone.0145087.ref033]\]. In addition, economic evaluations using modeling methods were assessed using Philips' checklist \[[@pone.0145087.ref034]\]. The quality assessment was conducted by one assessor (SH) and ambiguities were resolved by consulting another assessor (MB).

Synthesizing Data {#sec011}
-----------------

The results of the included CUAs were stratified into 4 subgroups by the type of previous treatments: 1) the cost-effectiveness of biologics in patients without previous treatment, 2) the cost-effectiveness of biologics in patients with previous conventional medical treatment, 3) the cost-effectiveness of biologics in patients with previous surgery, and 4) the cost-effectiveness of biologics in patients with previous biologic treatment. Biologic treatments were stratified under three dosing regimens: a single dose, an episodic treatment, or a maintenance treatment. ICERs were presented as principal outcomes. In this study, we analyzed the cost-effectiveness of biologics using the willingness-to-pay threshold of 35,000 €/QALY. A quantitative synthesis of the study results was not possible because of the heterogeneity in participants, interventions and study designs.

Results {#sec012}
=======

Literature Search {#sec013}
-----------------

The database search identified 1828 references, of which 461 were removed as duplicates, leaving 50 studies to be screened by abstracts and titles for further evaluation. After the assessment of the full text, 31 studies were excluded ([S2 File](#pone.0145087.s002){ref-type="supplementary-material"}) and 19 studies were included in the review. Additionally, six full-text articles were included, of which two were found from the bibliographies of already included studies \[[@pone.0145087.ref035],[@pone.0145087.ref036]\] and four from the structured abstracts identified by the literature search \[[@pone.0145087.ref019],[@pone.0145087.ref022],[@pone.0145087.ref037],[@pone.0145087.ref038]\]. The hand search revealed no further publications. Altogether, 25 studies were included in the review \[[@pone.0145087.ref019],[@pone.0145087.ref021],[@pone.0145087.ref022],[@pone.0145087.ref035]--[@pone.0145087.ref056]\]. Study selection is presented in a flow diagram in [Fig 1](#pone.0145087.g001){ref-type="fig"}.

![Flow chart of study selection.](pone.0145087.g001){#pone.0145087.g001}

Characteristics of Studies Included in the Review {#sec014}
-------------------------------------------------

All CUAs involved economic evaluation modeling, of which 17 and 7 were focused on CD and UC, respectively, while one study featured both diagnoses. IFX, ADA, NTZ, and CTZ were studied in 22, 8, two, and one CUAs, respectively. All studies were conducted in North America or in Europe. One study considered both direct and indirect costs \[[@pone.0145087.ref049]\]. Three studies were modelled for lifetime \[[@pone.0145087.ref043],[@pone.0145087.ref044],[@pone.0145087.ref046]\], while most studies used one year time horizon. The study designs, the interventions, and the comparators of the CUAs were heterogeneous. [Table 1](#pone.0145087.t001){ref-type="table"} presents the characteristics of the studies.

10.1371/journal.pone.0145087.t001

###### Characteristics of the studies.

![](pone.0145087.t001){#pone.0145087.t001g}

  Author, Year of publication, Country                            Patients                                                                                                                Biologic treatment                                                                                                                                                                                                                                                                            Comparative treatment                                                                                                                                                       Perspective         Time horizon, Type of modelling                                                                        Source of effectiveness                           Source of utility data, Instruments or valuation methods for utility measures                                                                                                                                                     Discount rate
  --------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------- ------------------------------------------------------------------------------------------------------ ------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------
  **Crohn's disease**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Ananthakrishnan et al. 2011, USA \[[@pone.0145087.ref039]\]     CD patients, who were in surgical remission after their first ileocecal resection                                       Upfront IFX or Tailored IFX                                                                                                                                                                                                                                                                   Antibiotic                                                                                                                                                                  Third-party payer   1 year, Decision tree model                                                                            Meta-analysis systematic review, cohort studies   Utility values derived from study by Casellas et al \[[@pone.0145087.ref057]\], for surgery and after surgery by a panel of UK gastroenterologists, EQ-5D, utilities valued using UK tariffs                                      \-
  Ananthakrishnan et al. 2012, USA \[[@pone.0145087.ref040]\]     Moderate-to severe luminal CD, loss of response to two prior TNF inhibitors                                             NTZ                                                                                                                                                                                                                                                                                           CTZ                                                                                                                                                                         Third-party payer   1 year, Decision tree model                                                                            RCTs, multi-center report, cohort study           Utility values derived from study by Gregor et al \[[@pone.0145087.ref058]\], SG, utility scores classified by CDAI                                                                                                               \-
  Arseneau et al. 2001, USA \[[@pone.0145087.ref041]\]            Fistulizing CD                                                                                                          First-line IFX, second-line 6MP+MET or IFX episodic reinfusion or First-line 6MP+MET, second-line IFX episodic reinfusion                                                                                                                                                                     6MP+MET                                                                                                                                                                     Third-party payer   1 year, Markov model                                                                                   Systematic review                                 Preference weights were directly elicited from CD patients and healthy individuals, SG                                                                                                                                            3% for costs and benefits
  Assasi et al. 2009, Canada \[[@pone.0145087.ref022]\]           Moderate-to severe CD (CDAI ≥ 200), refractory to conventional medical treatment                                        IFX 5 mg/kg induction and maintenance treatment or ADA induction treatment (160 mg at week 0, 80 mg at week 2) and maintenance treatment (40 mg)                                                                                                                                              Conventional medical treatment or ADA induction treatment (160 mg at week 0, 80 mg at week 2) and maintenance treatment (40 mg)                                             Third-party payer   5 years, Markov model                                                                                  Systematic review                                 Utility values derived from study by Gregor et al \[[@pone.0145087.ref058]\], SG                                                                                                                                                  5% for costs and QALYs
  Blackhouse et al. 2012, Canada \[[@pone.0145087.ref042]\]       Refractory to conventional medical treatment (CDAI \> 200)                                                              IFX 5 mg/kg induction and maintenance treatment or ADA induction treatment (160 mg at week 0, 80 mg at week 2) and maintenance treatment (40 mg)                                                                                                                                              Conventional medical treatment or ADA induction treatment (160 mg at week 0, 80 mg at week 2) and maintenance treatment (40 mg)                                             Third-party payer   5 years, Markov model                                                                                  Systematic review                                 Utility values derived from study by Gregor et al \[[@pone.0145087.ref058]\], SG                                                                                                                                                  5% for costs and QALYs
  Bodger et al. 2009, UK \[[@pone.0145087.ref043]\]               Moderate-to severe active CD, (CDAI \> 220)                                                                             IFX 5 mg/kg + conventional medical treatment or ADA 80 mg at week 0, 40 mg at week 2, 40 mg for maintenance + conventional treatment                                                                                                                                                          Conventional treatment                                                                                                                                                      Payer, UK NHS       60 years (lifetime), duration of treatment 1 or 2 years, Markov model                                  Systematic review                                 EQ-5D converted from CDAI (EQ-5D = 0.9168--0.0012 × CDAI, algorithm by Buxton et al \[[@pone.0145087.ref059]\])                                                                                                                   3.5% for costs and QALYs
  Clark et al. 2003, UK \[[@pone.0145087.ref044]\]                a, b) Severe active CD, c) Fistulizing CD                                                                               IFX 5 mg/kg single dose or IFX 5 mg/kg episodic re-treatment if lost response or IFX 5 mg/kg maintenance treatment                                                                                                                                                                            Placebo                                                                                                                                                                     Unclear             a\) Lifetime, b) Unclear, probably 1 year, c) 1 year, a) Markov model, b,c) Type of modeling unclear   a, b) RCTs, c)RCT                                 a, b) Utility values derived from study by Gregor et al \[[@pone.0145087.ref058]\], SG, utility scores corresponding to the exact CDAI states, c) Combination of CDAI and PDAI score into utility using an unpublished formulae   6% for costs and 1.5% for QALYs
  Doherty et al. 2012, USA \[[@pone.0145087.ref045]\]             CD patients undergone intestinal resection                                                                              IFX 5 mg/kg induction and maintenance treatment                                                                                                                                                                                                                                               AZA / 6MP                                                                                                                                                                   Societal            1 year, 5 years, Decision analysis model                                                               Meta-analysis                                     Utility values derived from study by Gregor et al \[[@pone.0145087.ref058]\], SG, utility scores classified by CDAI                                                                                                               3%
  Dretzke et al. 2011, UK \[[@pone.0145087.ref021]\]              Moderate-to-severe CD, refractory to conventional medical treatment                                                     IFX induction treatment or IFX maintenance treatment or ADA induction treatment or ADA maintenance treatment                                                                                                                                                                                  Conventional medical treatment or IFX induction treatment or ADA induction treatment                                                                                        Payer, UK NHS       1 year, Markov model                                                                                   Systematic review                                 Utility values derived from study by Gregor et al \[[@pone.0145087.ref058]\], assumptions for surgery, TTO, EQ-5D                                                                                                                 3.5% for costs and QALYs
  Jaisson-Hot et al. 2004, France \[[@pone.0145087.ref046]\]      Moderate-to-severe active ileocolonic non fistulizing CD (CDAI 220--440), resistant to conventional medical treatment   IFX with retreatment when patients relapse/do not respond or IFX maintenance treatment                                                                                                                                                                                                        Surgery involving conventional medical treatment                                                                                                                            Third-party payer   Lifetime, Markov model                                                                                 RCT, expert opinion, cohort study                 Utility values derived from study by Gregor et al \[[@pone.0145087.ref058]\], SG, utility scores classified by CDAI                                                                                                               5% for costs and QALYs
  Kaplan et al. 2007, USA \[[@pone.0145087.ref047]\]              CD patients, no response to 5 mg/kg of IFX                                                                              IFX dose escalation to 10 mg/kg                                                                                                                                                                                                                                                               ADA initiation                                                                                                                                                              Unclear             1 year, Decision analysis model                                                                        RCTs, cohort study                                Utility values derived from study by Gregor et al \[[@pone.0145087.ref058]\], SG, utility scores classified by CDAI                                                                                                               \-
  Lindsay et al. 2008, UK \[[@pone.0145087.ref048]\]              Active luminal non-fistulizing CD (CDAI 220--400) or Active fistulizing CD                                              IFX 5 mg/kg                                                                                                                                                                                                                                                                                   Conventional medical treatment                                                                                                                                              Payer, UK NHS       5 years, Markov model                                                                                  RCTs, cohort study                                Utility values derived from study by Casellas et al \[[@pone.0145087.ref057]\], for surgery and after surgery by a panel of UK gastroenterologists, EQ-5D, utilities valued using UK tariffs                                      3.5% for costs and QALYs
  Loftus et al. 2009, UK \[[@pone.0145087.ref049]\]               Moderate-to-severe CD                                                                                                   ADA                                                                                                                                                                                                                                                                                           Conventional medical treatment                                                                                                                                              Payer, UK NHS       1 year, Type of modeling unclear                                                                       RCTs                                              Utility values derived from study by Gregor et al \[[@pone.0145087.ref058]\], SG, utility scores classified by CDAI                                                                                                               3.5% for costs and QALYs
  Marchetti et al. 2013, Italy \[[@pone.0145087.ref050]\]         Newly diagnosed luminal moderate-to-severe CD patients                                                                  Top-down strategy: IFX 5 mg/kg+AZA à additional IFX 5 mg/kg+AZA à MPR+AZA                                                                                                                                                                                                                     Step-up strategy: MPR à MPR+AZA à IFX+AZA                                                                                                                                   Third-party payer   5 years, Markov model                                                                                  RCT, cohort studies                               EQ-5D and SF-6D converted from CDAI, SF-6D = 0.8129--0.00076 × CDAI, EQ-5D = 0.9168--0.0012 × CDAI, by Buxton et al                                                                                                               3.5% for costs and QALYs
  Marshall et al. 2002, Canada \[[@pone.0145087.ref019]\]         CD patients resistant to conventional medical treatment                                                                 IFX 5 mg/kg single dose, relapses treated with conventional treatment or IFX 5 mg/kg single dose, relapses treated with IFX 5 mg/kg single dose or IFX 5 mg/kg single dose with responding patients IFX 5 mg/kg maintenance treatment, relapses treated with conventional medical treatment   Conventional treatment or IFX 5 mg/kg single dose, relapses treated with conventional treatment or IFX 5 mg/kg single dose, relapses treated with IFX 5 mg/kg single dose   Third-party payer   1 year, Markov model                                                                                   RCTs, cohort study                                Utility values derived from study by Gregor et al \[[@pone.0145087.ref058]\], SG, utility scores classified by CDAI                                                                                                               \-
  Saito et al. 2013, UK \[[@pone.0145087.ref051]\]                Biologic-naive CD patients refractory to conventional medical treatment (CDAI 220--450)                                 IFX 5 mg/kg+AZA                                                                                                                                                                                                                                                                               IFX 5 mg/kg                                                                                                                                                                 Payer, UK NHS       1 year, Decision tree model                                                                            RCTs, observational study                         Utility values derived from study by Gregor et al \[[@pone.0145087.ref058]\], expert opinion data for non-responding active disease, SG, utility scores classified by CDAI                                                        \-
  Tang et al. 2012, USA \[[@pone.0145087.ref052]\]                Moderate-to-severe CD (CDAI 220--450), refractory to conventional medical treatment and naïve to biologics              ADA or CTZ or NTZ                                                                                                                                                                                                                                                                             IFX                                                                                                                                                                         Third-party payer   1 year, Decision analytic model                                                                        RCTs                                              Utility values derived from study by Gregor et al \[[@pone.0145087.ref058]\], SG, utility scores classified by CDAI                                                                                                               \-
  Yu et al. 2009, USA \[[@pone.0145087.ref056]\]                  Active moderate-to-severe CD, candidate for anti-TNF maintenance treatment                                              ADA (40 mg every other week) maintenance treatment                                                                                                                                                                                                                                            IFX 5 mg/kg maintenance treatment                                                                                                                                           Third-party payer   1 year, Type of modeling unclear                                                                       RCTs                                              Utility values derived from study by Gregor et al \[[@pone.0145087.ref058]\], SG, utility scores classified by CDAI                                                                                                               \-
  **Ulcerative colitis**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Assasi et al. 2009, Canada \[[@pone.0145087.ref022]\]           Moderate-to-severe UC, refractory to conventional medical treatment                                                     IFX 5 mg/kg followed by switching to ADA 160 mg when relapse or IFX 5 mg/kg followed by IFX 10 mg/kg dose escalation when relapse                                                                                                                                                             Conventional medical treatment or IFX 5 mg/kg followed by switching to ADA 160 mg when relapse                                                                              Third-party payer   5 years, Markov model                                                                                  Systematic literature review                      TTO, Utility weights elicited from UC patients                                                                                                                                                                                    5% for costs and QALYs
  Bryan et al. 2008, UK \[[@pone.0145087.ref037]\]                Acute exacerbation of UC that require hospitalization, inadequate response to conventional medical treatment            IFX 5 mg/kg+IV CST                                                                                                                                                                                                                                                                            Placebo or CYC or Surgery                                                                                                                                                   Payer, UK NHS       1 year, Decision analytic model                                                                        RCTs                                              EQ-5D, Utility weights derived from UC patients                                                                                                                                                                                   3.5% for costs and QALYs
  Chaudhary et al. 2013, Netherlands \[[@pone.0145087.ref036]\]   Severely active UC, hospitalized with an acute exacerbation of UC, refractory to IV CST                                 IFX 5 mg/kg                                                                                                                                                                                                                                                                                   IV CYC or Surgery                                                                                                                                                           Third-party payer   1 year, Decision analytic model, beyond the first year a Markov model                                  RCTs                                              EQ-5D, valued using UK tariffs, TTO for post-surgery complications, Utility scores classified by SCAI, Utility weights derived from UC patients                                                                                   4% for costs, 1.5% for QALYs
  Hyde et al. 2007, UK \[[@pone.0145087.ref038]\]                 Moderate-to-severe active UC, an inadequate response to conventional medical treatment                                  IFX 5 mg/kg                                                                                                                                                                                                                                                                                   Conventional treatment                                                                                                                                                      Payer, UK NHS       10 years, Markov model                                                                                 RCTs                                              EQ-5D, Utility weights derived from UC patients                                                                                                                                                                                   3.5% for costs and QALYs
  Punekar et al. 2010, UK \[[@pone.0145087.ref035]\]              Severely active UC, hospitalized with an acute exacerbation of UC, refractory to IV CST                                 IFX 5 mg/kg + IV CST                                                                                                                                                                                                                                                                          IV CST or CYC+IV CST or Surgery                                                                                                                                             Payer, UK NHS       1 year, Decision analytic model, beyond the first year a Markov model                                  A network meta-analysis                           EQ-5D, valued using UK tariffs, TTO for post-surgery complications, Utility scores classified by SCAI, Utility weights derived from UC patients                                                                                   3.5% for costs and QALYs
  Tsai et al. 2008, UK \[[@pone.0145087.ref053]\]                 Moderate-to-severe UC                                                                                                   Scheduled maintenance treatment with IFX 5 mg/kg                                                                                                                                                                                                                                              Conventional medical treatment                                                                                                                                              Payer, UK NHS       10 years, Markov model                                                                                 RCTs                                              EQ-5D, valued using UK tariffs, TTO for post-surgery complications, Utility scores classified by SCAI, Utility weights derived from UC patients                                                                                   3.5% for costs and QALYs
  Ung et al. 2014, Canada \[[@pone.0145087.ref054]\]              Moderate or moderately severe UC, CST-dependent and refractory to thiopurine                                            IFX 5 mg/kg                                                                                                                                                                                                                                                                                   Conventional medical treatment                                                                                                                                              Third-party payer   10 years, Markov model                                                                                 RCTs, real life rates                             TTO, VAS, Utility weights derived from UC patients                                                                                                                                                                                5% for costs and QALYs
  Xie et al. 2009, Canada \[[@pone.0145087.ref055]\]              Moderate-to-severe UC, refractory to conventional medical treatment                                                     IFX 5 mg/kg followed by IFX 10 mg/kg dose escalation when relapse or IFX 5 mg/kg followed by switching to ADA 160 mg when relapse                                                                                                                                                             Conventional medical treatment                                                                                                                                              Third-party payer   5 years, Markov model                                                                                  Fixed-effect meta-analysis                        TTO, Utility weights derived from UC patients                                                                                                                                                                                     5% for costs and QALYs

^→^, Transition because of the clinical worsening in the earlier state; 6MP, Mercaptopurine; ADA, Adalimumab; AZA, Azathioprine; CD, Crohn's disease; CDAI, Crohn's disease activity index; CST, Corticosteroid; CTZ, Certolizumab pegol; CYC, Cyclosporine; EQ-5D, European Quality of Life Instrument 5 D; IBDQ-36, Inflammatory Bowel Disease Questionnaire 36; IFX, Infliximab; IV, Intravenous; MET, Metronidazole; MPR, Methylprednisolone; NTZ, Natalizumab; PDAI, Pouchitis Activity Index; QALY, Quality-Adjusted Life Year; RCT, Randomized controlled trial; SCAI, Simple Clinical Colitis Activity Index; SF-6D, Short Form-6 dimension; SG, Standard gamble; TNF, Tumor necrosis factor; TTO, Time Trade-Off; UC, Ulcerative colitis; UK NHS, National Health Service (England); VAS, Visual Analog Scale.

Cost-Effectiveness of Biologics in Patients with No Previous Treatment {#sec015}
----------------------------------------------------------------------

In two studies, the cost-effectiveness of biologics was evaluated in CD patients with no previous treatment ([Table 2](#pone.0145087.t002){ref-type="table"}) \[[@pone.0145087.ref041],[@pone.0145087.ref050]\]. In comparison with conventional drugs for the treatment of fistulizing CD, ICERs ascended in excess of 400,000 €/QALY \[[@pone.0145087.ref041]\] while for newly diagnosed luminal CD IFX was dominant \[[@pone.0145087.ref050]\]. No CEAs of biologics in UC patients without earlier treatment were found ([Table 3](#pone.0145087.t003){ref-type="table"}).

10.1371/journal.pone.0145087.t002

###### Cost-effectiveness of biologics for the treatment of Crohn's disease (CD).
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  Study                                                                                            Intervention (Biologic treatment)            Comparison treatment                ICER[^a^](#t002fn002){ref-type="table-fn"} €[^d^](#t002fn005){ref-type="table-fn"}/QALY (including only direct[^b^](#t002fn003){ref-type="table-fn"} costs)   ICER[^a^](#t002fn002){ref-type="table-fn"} €[^d^](#t002fn005){ref-type="table-fn"}/QALY (including both direct[^b^](#t002fn003){ref-type="table-fn"} and indirect[^c^](#t002fn004){ref-type="table-fn"} costs)   Results of deterministic sensitivity analysis (€[^d^](#t002fn005){ref-type="table-fn"}/QALY)   Source of research funding
  ------------------------------------------------------------------------------------------------ -------------------------------------------- ----------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Cost-effectiveness of biologics in CD patients with no previous treatment**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Arseneau et al. 2001 \[[@pone.0145087.ref041]\]                                                  First-line IFX                               6MP+MET                             438,617                                                                                                                                                       \-                                                                                                                                                                                                               219,353--dominance by comparison treatment                                                     NIDDK
                                                                                                   IFX episodic reinfusion                      6MP+MET                             445,477                                                                                                                                                       \-                                                                                                                                                                                                               127,314--dominance by comparison treatment                                                     NIDDK
                                                                                                   Second-line IFX episodic reinfusion          6MP+MET                             465,394                                                                                                                                                       \-                                                                                                                                                                                                               155,109--comparison treatment is cost-saving                                                   NIDDK
  Marchetti et al. 2013 \[[@pone.0145087.ref050]\]                                                 Top-down: IFX                                Step-up: IFX                        Dominance by intervention treatment                                                                                                                           \-                                                                                                                                                                                                               Dominance by intervention treatment--93,401                                                    None declared
  **Cost-effectiveness of biologics in CD patients with earlier conventional medical treatment**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Assasi et al. 2009 \[[@pone.0145087.ref022]\]                                                    IFX                                          Conventional medical treatment      155,295                                                                                                                                                       \-                                                                                                                                                                                                               142,742--254,029                                                                               Canadian federal, provincial, and territorial governments
                                                                                                   ADA                                          Conventional medical treatment      134,643                                                                                                                                                       \-                                                                                                                                                                                                               120,307--474,352                                                                               Canadian federal, provincial, and territorial governments
                                                                                                   IFX                                          ADA                                 314,250                                                                                                                                                       \-                                                                                                                                                                                                               154,436--Dominance by comparison treatment                                                     Canadian federal, provincial, and territorial governments
  Blackhouse et al. 2012 \[[@pone.0145087.ref042]\]                                                IFX                                          Conventional medical treatment      164,626                                                                                                                                                       \-                                                                                                                                                                                                               74,434--344,212                                                                                Not stated, one of authors has received an honorarium from Abbott and acted as a consultant for Centocor Ortho Biotech Services
                                                                                                   ADA                                          Conventional medical treatment      142,733                                                                                                                                                       \-                                                                                                                                                                                                               63,679--297,508                                                                                Not stated, one of authors has received an honorarium from Abbott and acted as a consultant for Centocor Ortho Biotech Services
                                                                                                   IFX                                          ADA                                 331,132                                                                                                                                                       \-                                                                                                                                                                                                               157,253--Dominance by comparison treatment                                                     Not stated, one of authors has received an honorarium from Abbott and acted as a consultant for Centocor Ortho Biotech Services
  Bodger et al. 2009 \[[@pone.0145087.ref043]\]                                                    IFX                                          Conventional treatment              31,982 (Duration of treatment 1 year); 35,759 (Duration of treatment 2 years)                                                                                 \-                                                                                                                                                                                                               31,227--Dominance by comparison treatment                                                      The Welsh Office for Research and Development for Health and Social Care
                                                                                                   ADA                                          Conventional treatment              12,071 (Duration of treatment 1 year); 17,309 (Duration of treatment 2 years)                                                                                 \-                                                                                                                                                                                                               12,692--304,912                                                                                The Welsh Office for Research and Development for Health and Social Care
  Clark et al. 2003 \[[@pone.0145087.ref044]\]                                                     IFX single dose                              Placebo                             a\) 11,725 b) 236,836 (scenario 1) 163,179 (scenario 2) c) 178,503--215,253                                                                                   \-                                                                                                                                                                                                               b\) 236,836--529,754 (scenario 1); 163,179--373,921 (scenario 2) c) 143,502--215,253           NICE (UK)
                                                                                                   IFX episodic re-treatment if lost response   Placebo                             a\) 18,200 b) 126,459 (scenario 1); 108,530 (scenario 2)                                                                                                      \-                                                                                                                                                                                                               a\) 34,651--95,901 b) 82,197--126,459 (scenario 1); 70,544--108,530 (scenario 2)               NICE (UK)
                                                                                                   IFX maintenance treatment                    Placebo                             a\) 147,702                                                                                                                                                   \-                                                                                                                                                                                                               \-                                                                                             NICE (UK)
  Dreztke et al. 2011 \[[@pone.0145087.ref021]\]                                                   IFX induction treatment                      Conventional medical treatment      Dominance by intervention treatment (Severe CD); 162,941 (Moderate CD)                                                                                        \-                                                                                                                                                                                                               17,346--123,198                                                                                NICE (UK)
                                                                                                   IFX maintenance treatment                    Conventional medical treatment      118,015 (Severe CD); 549,335 (Moderate CD)                                                                                                                    \-                                                                                                                                                                                                               63,127--2,764,027                                                                              NICE (UK)
                                                                                                   ADA induction treatment                      Conventional medical treatment      Dominance by intervention treatment                                                                                                                           \-                                                                                                                                                                                                               Dominance by intervention treatment                                                            NICE (UK)
                                                                                                   ADA maintenance treatment                    Conventional medical treatment      13,387 (Severe CD); 276,539 (Moderate CD)                                                                                                                     \-                                                                                                                                                                                                               Dominance by intervention treatment--1,180,345                                                 NICE (UK)
                                                                                                   IFX maintenance treatment                    IFX induction treatment             8,689,409 (Severe CD); 24,012,483 (Moderate CD)                                                                                                               \-                                                                                                                                                                                                               553,635--8,568,483                                                                             NICE (UK)
                                                                                                   ADA maintenance treatment                    ADA induction treatment             8,603,033 (Severe CD); 24,012,483 (Moderate CD)                                                                                                               \-                                                                                                                                                                                                               Dominance by intervention treatment--8,810,335                                                 NICE (UK)
  Jaisson-Hot et al. 2004 \[[@pone.0145087.ref046]\]                                               IFX re-treatment                             Surgery                             77,002                                                                                                                                                        \-                                                                                                                                                                                                               77,002--dominance by comparison treatment                                                      Not stated
                                                                                                   IFX maintenance treatment                    Surgery                             947,769                                                                                                                                                       \-                                                                                                                                                                                                               947,769--dominance by comparison treatment                                                     Not stated
  Lindsay et al. 2008 \[[@pone.0145087.ref048]\]                                                   IFX                                          Conventional medical treatment      45,137 (Severe active luminal CD); 51,397 (Fistulizing CD)                                                                                                    \-                                                                                                                                                                                                               41,032--67,111 (Severe active luminal CD); 46,724--76,367 (Fistulizing CD)                     Schering Plough Ltd
  Loftus et al. 2009 \[[@pone.0145087.ref049]\]                                                    ADA                                          Conventional medical treatment      27,751 (Severe CD); 58,271 (Moderate-to-severe CD)                                                                                                            9,069 (Severe CD); 42,554 (Moderate-to-severe CD)                                                                                                                                                                11,315--59,133 (Severe CD); 30,876--99,455 (Moderate-to-severe CD)                             Abbott Laboratories
  Marshall et al. 2002 \[[@pone.0145087.ref019]\]                                                  IFX single dose                              Conventional treatment              162,181                                                                                                                                                       \-                                                                                                                                                                                                               34,908--Dominance by comparison treatment                                                      CCOHTA (now CADTH)
                                                                                                   IFX single dose with re-treatment            IFX single dose                     429,715                                                                                                                                                       \-                                                                                                                                                                                                               Dominance by intervention treatment--533,605                                                   CCOHTA (now CADTH)
                                                                                                   IFX maintenance treatment                    IFX single dose with re-treatment   623,013                                                                                                                                                       \-                                                                                                                                                                                                               1,620--736,716                                                                                 CCOHTA (now CADTH)
  Saito et al. 2013 \[[@pone.0145087.ref051]\]                                                     IFX+AZA                                      IFX                                 34,549                                                                                                                                                        \-                                                                                                                                                                                                               23,776--63,178                                                                                 CISA
  Tang et al. 2012 \[[@pone.0145087.ref052]\]                                                      ADA                                          IFX                                 \-                                                                                                                                                            \-                                                                                                                                                                                                               \-                                                                                             Not stated
                                                                                                   CTZ                                          IFX                                 \-                                                                                                                                                            \-                                                                                                                                                                                                               \-                                                                                             Not stated
                                                                                                   NTZ                                          IFX                                 \-                                                                                                                                                            \-                                                                                                                                                                                                               \-                                                                                             Not stated
  Yu et al. 2009 \[[@pone.0145087.ref056]\]                                                        ADA maintenance treatment                    IFX maintenance treatment           Dominance by intervention treatment                                                                                                                           \-                                                                                                                                                                                                               Dominance by intervention treatment                                                            Abbott Laboratories
  **Cost-effectiveness of biologics in CD patients with earlier surgical treatment**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Ananthakrishnan et al. 2011 \[[@pone.0145087.ref039]\]                                           Upfront IFX                                  Antibiotic                          2,268,986                                                                                                                                                     \-                                                                                                                                                                                                               594,301--5,485,175                                                                             None declared, one author receives research support from Procter and Gamble and Warner Chilcott
                                                                                                   Tailored IFX                                 Antibiotic                          Dominance by comparison treatment                                                                                                                                                                                                                                                                                                                                              Dominancy by comparison treatment                                                              None declared, one author receives research support from Procter and Gamble and Warner Chilcott
  Doherty et al. 2012 \[[@pone.0145087.ref045]\]                                                   IFX                                          AZA/6MP                             1,449,979 (Time horizon 1 year); 1,823,102 (Time horizon 5 years)                                                                                             \-                                                                                                                                                                                                               1,449,979--Dominance by comparison treatment                                                   Pfizer Inc. and Merck & Co. One of authors receives research funding from Proctor & Gamble, Shire and Salix
  **Cost-effectiveness of biologics in CD patients with earlier biological treatment**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Ananthakrishnan et al. 2012 \[[@pone.0145087.ref040]\]                                           NTZ                                          CTZ                                 314,020                                                                                                                                                       \-                                                                                                                                                                                                               Dominance by intervention treatment---Dominance by comparison treatment                        None declared
  Kaplan et al. 2007 \[[@pone.0145087.ref047]\]                                                    IFX dose escalation                          ADA                                 311,432                                                                                                                                                       \-                                                                                                                                                                                                               46,862--Dominance by comparison treatment                                                      None declared, authors have received research grants from UCB Pharma, Abbott Laboratories, Centocor, Bristol-Myers Squibb, Elan Pharmaceuticals, Prometheus Laboratories, Otsuka America Pharmaceuticals Inc

ADA, Adalimumab; CEGIIR, Centre of Excellence for Gastrointestinal Inflammation and Immunity Research; CST, Corticosteroid; CYC, Cyclosporine; IFX, Infliximab; IV, Intravenous; NICE, National Institute for Health and Care Excellence; RCT, Randomized controlled trial; QALY, Quality-Adjusted Life Year; TTO, Time Trade-off; VAS, Visual analog scale.

^a^The difference in costs divided by the difference in health effects.

^b^The resources consumed.

^c^Productivity costs for the patient and family members.

^d^All costs converted into 2014 euro.

10.1371/journal.pone.0145087.t003

###### Cost-effectiveness of biologics for the treatment of ulcerative colitis (UC).

![](pone.0145087.t003){#pone.0145087.t003g}

  Study                                                                                            Intervention (Biologic treatment)                  Comparison treatment                            ICER[^a^](#t003fn002){ref-type="table-fn"} €[^d^](#t003fn005){ref-type="table-fn"}/QALY (including only direct[^b^](#t003fn003){ref-type="table-fn"} costs)   ICER[^a^](#t003fn002){ref-type="table-fn"} €[^d^](#t003fn005){ref-type="table-fn"}/QALY (including both direct[^b^](#t003fn003){ref-type="table-fn"} and indirect[^c^](#t003fn004){ref-type="table-fn"} costs)   Results of deterministic sensitivity analysis (€[^d^](#t003fn005){ref-type="table-fn"}/QALY)                                 Source of research funding, Conflict of interest of authors
  ------------------------------------------------------------------------------------------------ -------------------------------------------------- ----------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------
  **Cost-effectiveness of biologics in UC patients with earlier conventional medical treatment**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Assasi et al. 2009 \[[@pone.0145087.ref022]\]                                                    IFX followed by IFX dose escalation when relapse   Conventional medical treatment                  407,499                                                                                                                                                       \-                                                                                                                                                                                                               294,007--629,598                                                                                                             Canadian federal, provincial, and territorial governments
                                                                                                   IFX followed by switching to ADA when relapse      Conventional medical treatment                  253,537                                                                                                                                                       \-                                                                                                                                                                                                               191,701--373,298                                                                                                             Canadian federal, provincial, and territorial governments
                                                                                                   IFX followed by IFX dose escalation when relapse   IFX followed by switching to ADA when relapse   Dominance by comparison treatment                                                                                                                             \-                                                                                                                                                                                                               \-                                                                                                                           Canadian federal, provincial, and territorial governments
  Bryan et al. 2008 \[[@pone.0145087.ref037]\]                                                     IFX                                                CYC                                             33,486                                                                                                                                                        \-                                                                                                                                                                                                               2,399--108,262                                                                                                               NICE (UK)
                                                                                                   IFX                                                Placebo                                         20,829                                                                                                                                                                                                                                                                                                                                                                         7,745--24,268                                                                                                                NICE (UK)
                                                                                                   IFX                                                Surgery                                         24,293                                                                                                                                                        \-                                                                                                                                                                                                               2,470--109,612                                                                                                               NICE (UK)
  Chaudhary et al. 2013 \[[@pone.0145087.ref036]\]                                                 IFX                                                IV CYC                                          26,479                                                                                                                                                        \-                                                                                                                                                                                                               17,609--38,985                                                                                                               Merck & Co
                                                                                                   IFX                                                Surgery                                         15,967                                                                                                                                                        \-                                                                                                                                                                                                               11,614--24,475                                                                                                               Merck & Co
  Hyde et al. 2007 \[[@pone.0145087.ref038]\]                                                      IFX                                                Conventional treatment                          72,711                                                                                                                                                        \-                                                                                                                                                                                                               29,363--101,989                                                                                                              NICE (UK)
  Punekar et al. 2010 \[[@pone.0145087.ref035]\]                                                   IFX                                                IV CST                                          19,198                                                                                                                                                        \-                                                                                                                                                                                                               Dominance by intervention treatment--94,322                                                                                  Schering-Plough Ltd
                                                                                                   IFX                                                CYC+IV CST                                      30,871                                                                                                                                                        \-                                                                                                                                                                                                               Dominance by intervention treatment--108,272                                                                                 Schering-Plough Ltd
                                                                                                   IFX                                                Surgery                                         22,161                                                                                                                                                        \-                                                                                                                                                                                                               Dominance by intervention treatment--109,279                                                                                 Schering-Plough Ltd
  Tsai et al. 2008 \[[@pone.0145087.ref053]\]                                                      IFX maintenance treatment                          Conventional medical treatment                  46,041 (responders only); 33,067 (remission only)                                                                                                             \-                                                                                                                                                                                                               353,367--144,921 (responders only); 24,726--78,511 (remission only)                                                          Schering-Plough Ltd
  Ung et al. 2014 \[[@pone.0145087.ref054]\]                                                       IFX                                                Conventional medical treatment                  Source of effectiveness based on RCTs: 115,639 (TTO); 99,663 (VAS), Source of effectiveness based on real-life studies: 66,949 (TTO); 60,101 (VAS)            \-                                                                                                                                                                                                               Source of effectiveness based on RCTs: 54,777--248,016, Source of effectiveness based on real-life studies: 31,192--94,337   CEGIIR and the Alberta Innovates---Health Solutions supported Alberta IBD Consortium
  Xie et al. 2009 \[[@pone.0145087.ref055]\]                                                       IFX dose escalating when relapse                   Conventional medical treatment                  407,499                                                                                                                                                       \-                                                                                                                                                                                                               303,515--629,598                                                                                                             Not stated, Conflict of interest: Eli Lilly Canada Inc, GlaxoSmithKline Inc, Abbott Laboratories Ltd, Janssen-Ortho Inc., Hoffman-La Roche Ltd
                                                                                                   IFX switching to ADA when relapse                  Conventional medical treatment                  253,537                                                                                                                                                       \-                                                                                                                                                                                                               193,349--373,298                                                                                                             Not stated, Conflict of interest: Eli Lilly Canada Inc, GlaxoSmithKline Inc, Abbott Laboratories Ltd, Janssen-Ortho Inc., Hoffman-La Roche Ltd

ADA, Adalimumab; CEGIIR, Centre of Excellence for Gastrointestinal Inflammation and Immunity Research; CST, Corticosteroid; CYC, Cyclosporine; IFX, Infliximab; IV, Intravenous; NICE, National Institute for Health and Care Excellence; RCT, Randomized controlled trial; QALY, Quality-Adjusted Life Year; TTO, Time Trade-off; VAS, Visual analog scale.

^a^The difference in costs divided by the difference in health effects.

^b^The resources consumed.

^c^Productivity costs for the patient and family members.

^d^All costs converted into 2014 euro.

Cost-Effectiveness of Biologics in Patients with Previous Conventional Medical Treatment {#sec016}
----------------------------------------------------------------------------------------

The cost-effectiveness of biologics in CD patients with previous conventional medical treatment was investigated in 12 studies ([Table 2](#pone.0145087.t002){ref-type="table"}) \[[@pone.0145087.ref019],[@pone.0145087.ref021],[@pone.0145087.ref022],[@pone.0145087.ref042]--[@pone.0145087.ref044],[@pone.0145087.ref046],[@pone.0145087.ref048],[@pone.0145087.ref049],[@pone.0145087.ref051],[@pone.0145087.ref052],[@pone.0145087.ref056]\]. For CD, ICERs for the biologics ranged from dominance to 549,335 €/QALY when compared with those of conventional medical treatment \[[@pone.0145087.ref019],[@pone.0145087.ref021],[@pone.0145087.ref022],[@pone.0145087.ref042],[@pone.0145087.ref043],[@pone.0145087.ref048],[@pone.0145087.ref049]\]. ADA as an intervention treatment resulted in more frequently lower ICERs than did IFX in comparison with conventional medical treatment \[[@pone.0145087.ref021],[@pone.0145087.ref022],[@pone.0145087.ref042],[@pone.0145087.ref043]\]. IFX in comparison with surgery was not found to be cost-effective, with ICERs in excess of 77,000 €/QALY \[[@pone.0145087.ref046]\]. Between biologics cost-effectiveness was investigated in four studies \[[@pone.0145087.ref022],[@pone.0145087.ref042],[@pone.0145087.ref052],[@pone.0145087.ref056]\]. ICERs above 300,000 €/QALY were seen when comparing IFX with ADA \[[@pone.0145087.ref022],[@pone.0145087.ref042]\], while ADA maintenance treatment appeared to be dominant in comparison with IFX maintenance treatment \[[@pone.0145087.ref056]\].

Two studies evaluated the cost-effectiveness of biologics for different activity levels of CD resulting in more favorable ICERs for severe CD than for moderate CD \[[@pone.0145087.ref021],[@pone.0145087.ref049]\]. The cost-effectiveness of biologics for fistulizing CD was examined in two studies (ICERs above 51,000 €/QALY) \[[@pone.0145087.ref044],[@pone.0145087.ref048]\] and for luminal CD in two studies (ICERs above 45,000 €/QALY) \[[@pone.0145087.ref046],[@pone.0145087.ref048]\]. Biologic induction treatment resulted in lower ICERs than maintenance treatment \[[@pone.0145087.ref021]\]. In one study, IFX and corticosteroid combination treatment was shown to be cost-effective in comparison with IFX monotherapy \[[@pone.0145087.ref051]\]. One study found more favorable ICER when including both direct and indirect costs than only direct costs \[[@pone.0145087.ref049]\]. The ICERs of the studies using lifetime horizon ranged from 11,725 to 947,769 €/QALY \[[@pone.0145087.ref043],[@pone.0145087.ref044],[@pone.0145087.ref046]\].

Eight CUAs evaluated the cost-effectiveness of biologics in UC patients with previous conventional medical treatment ([Table 3](#pone.0145087.t003){ref-type="table"}) \[[@pone.0145087.ref022],[@pone.0145087.ref035]--[@pone.0145087.ref038],[@pone.0145087.ref053]--[@pone.0145087.ref055]\]. ICER remained below 35,000 €/QALY when comparing IFX with either conventional medical treatment, surgery, or placebo treatment for UC patients with acute exacerbation requiring hospitalization \[[@pone.0145087.ref035]--[@pone.0145087.ref037]\]. When investigating the cost-effectiveness of IFX for patients with moderate-to-severe UC, ICER ranged from 33,067 €/QALY to 407,499 €/QALY \[[@pone.0145087.ref022],[@pone.0145087.ref038],[@pone.0145087.ref053]--[@pone.0145087.ref055]\].

Cost-Effectiveness of Biologics in Patients with Previous Surgery {#sec017}
-----------------------------------------------------------------

The cost-effectiveness of biologics in CD patients having undergone intestinal resection was investigated in two CUAs ([Table 2](#pone.0145087.t002){ref-type="table"}) \[[@pone.0145087.ref039],[@pone.0145087.ref045]\]. IFX in comparison with conventional medical treatment was not cost-effective, producing extremely unfavorable ICERs above 1,400,000 €/QALY. No studies investigated the cost-effectiveness of biologics in UC patients with previous surgery ([Table 3](#pone.0145087.t003){ref-type="table"}).

Cost-Effectiveness of Biologics in Patients with Previous Biologic Treatment {#sec018}
----------------------------------------------------------------------------

The cost-effectiveness of biologics in CD patients with prior biologic treatment was investigated in two CUAs ([Table 2](#pone.0145087.t002){ref-type="table"}) \[[@pone.0145087.ref040],[@pone.0145087.ref047]\]. Neither IFX dose escalation in comparison with second-line ADA nor third-line CTZ in comparison with NTZ was cost-effective (ICERs above 300,000 €/QALY). No studies evaluated the cost-effectiveness of biologics in UC patients with prior TNF inhibitor treatment ([Table 3](#pone.0145087.t003){ref-type="table"}).

Effectiveness Data {#sec019}
------------------

In all studies, the source of effectiveness was based on at least one randomized controlled trial (RCT). One study used real life data published by specialized inflammatory bowel disease clinics and compared those findings with data from RCTs \[[@pone.0145087.ref054]\].

In 13 studies focused on CD, utility values were obtained by the Standard Gamble (SG) valuation technique \[[@pone.0145087.ref019],[@pone.0145087.ref022],[@pone.0145087.ref040]--[@pone.0145087.ref042],[@pone.0145087.ref044]--[@pone.0145087.ref047],[@pone.0145087.ref049],[@pone.0145087.ref051],[@pone.0145087.ref052],[@pone.0145087.ref056]\]. In twelve studies, the utilities were derived from study by Gregor et al \[[@pone.0145087.ref058]\] which used the SG method in CD patients to define utility scores and correlated them with the Crohn's disease Activity Index (CDAI) \[[@pone.0145087.ref019],[@pone.0145087.ref022],[@pone.0145087.ref040],[@pone.0145087.ref042],[@pone.0145087.ref044]--[@pone.0145087.ref047],[@pone.0145087.ref049],[@pone.0145087.ref051],[@pone.0145087.ref052],[@pone.0145087.ref056]\]. In two studies \[[@pone.0145087.ref039],[@pone.0145087.ref048]\], health state preferences were driven from the study by Casellas et al \[[@pone.0145087.ref057]\] which estimated health state preferences of Spanish CD patients using the European Quality of Life Instrument 5 D (EQ-5D) and converted to utilities using UK tariffs. In two studies \[[@pone.0145087.ref043],[@pone.0145087.ref050]\] the estimated EQ-5D utility scores were converted from CDAI scores based on the algorithm developed by Buxton et al \[[@pone.0145087.ref059]\].

In three studies concerning UC \[[@pone.0145087.ref035],[@pone.0145087.ref036],[@pone.0145087.ref053]\], the utility scores were obtained from an UC patient survey carried out in Cardiff Hospital using the EQ-5D and valued using UK tariffs \[[@pone.0145087.ref060]\]. Utilities were further classified into health states by a Simple Clinical Colitis Activity Index (SCAI). Two studies \[[@pone.0145087.ref022],[@pone.0145087.ref055]\] used utilities from patients using Time Trade-off (TTO) valuation technique \[[@pone.0145087.ref061]\].

Quality Assessment {#sec020}
------------------

The results of the quality assessment are shown in [Fig 2](#pone.0145087.g002){ref-type="fig"}. The mean amount of fulfilled criteria were 24.9 out of 35 (median 26, range 14--30), 29.6 out of 57 (median 29, range 14--46), and 18.2 out of 24 (median 18, range 10--23) for Drummond's checklist, Philip's checklist, and the CHEERS guideline, respectively. Studies by Assasi et al, Bryan et al, and Dretzke et al, which all are Health Technology Assessment (HTA) reports, fulfilled most criteria of the applicable items \[[@pone.0145087.ref021],[@pone.0145087.ref022],[@pone.0145087.ref037]\]. The quality elements most commonly omitted from the economic analyses were information on adjustments for data identification, baseline data, treatment effects, data incorporation, and assessment of uncertainty ([S2 Table](#pone.0145087.s004){ref-type="supplementary-material"}).

![Quality assessment of the included studies.](pone.0145087.g002){#pone.0145087.g002}

Discussion {#sec021}
==========

Altogether, 25 studies were included in this systematic review. The number of the included studies in this review was higher than in previously published reviews for IBD \[[@pone.0145087.ref018]--[@pone.0145087.ref022]\]. However, it is noteworthy that articles by Blackhouse et al and Xie et al are part of the study by Assasi et al \[[@pone.0145087.ref022],[@pone.0145087.ref042],[@pone.0145087.ref055]\]. A majority of the included studies used IFX or ADA as an intervention treatment, while NTZ and CTZ were investigated only in few studies, and none of the studies considered golimumab. Because of the variability in data input and heterogeneous study designs, the quantitative synthesis of the studies was not possible.

On the basis of the current review and willingness-to-pay threshold of 35,000 €/QALY, biologics in comparison with conventional medical treatment and placebo treatment were found to be cost-effective for severe CD in remission induction, while for maintenance treatment cost-effectiveness remained unclear. Biologics were not cost-effective in comparison with surgery for the treatment of severe CD. In moderate CD, biologics did not seem to be cost-effective. Biologics were found not to be cost-effective among CD patients having undergone intestinal resection. ADA was shown to be a more cost-effective biologic treatment option than IFX. Cost-effectiveness between individual biologics remained unclear, however.

Biologics were cost-effective for the treatment of acute exacerbation of severely active UC when compared with either conventional medical treatment, surgery, or placebo treatment. For moderate UC, biologics were not cost-effective. The cost-effectiveness between different biologics remained unclear in UC.

The literature search found five earlier published systematic reviews of the cost-effectiveness of biologics for IBDs \[[@pone.0145087.ref018]--[@pone.0145087.ref022]\]. In previous reviews, the conclusions have been contradictory and partially unreliable due to a low amount of included CUAs. Four out of five previous reviews evaluated the cost-effectiveness of biologics for CD \[[@pone.0145087.ref018]--[@pone.0145087.ref021]\], while one assessed the cost-effectiveness of biologics in both CD and UC \[[@pone.0145087.ref022]\]. IFX was the only biologic treatment in four reviews \[[@pone.0145087.ref019]--[@pone.0145087.ref022]\]. Meanwhile, the latest systematic review by Tang et al included IFX, ADA, CTZ, and NTZ and came to a conclusion that the biologics are cost-effective for CD in certain clinical situations which was congruent with this review \[[@pone.0145087.ref018]\]. The earlier review by Assasi et al \[[@pone.0145087.ref022]\] included one CUA \[[@pone.0145087.ref053]\] showing that scheduled maintenance treatment with IFX is a cost-effective option for UC \[[@pone.0145087.ref022]\]. The studies included in our review focused mainly on induction treatment and revealed no further evidence of the cost-effectiveness of biologic maintenance treatment for UC.

An important issue affecting the conclusions of CEAs relates to the established willingness-to-pay threshold. In the UK, the National Institute of Health and Clinical Excellence (NICE) supports treatments with ICER no higher than 30,000 £ (\~35,000 €) per QALY \[[@pone.0145087.ref062]\], which we used as a threshold in this study. However, there has been much debate as to whether this threshold is too low, and many health care systems have not set a cost-effectiveness threshold at all \[[@pone.0145087.ref054]\]. The willingness-to-pay threshold commonly used by the Canadian Drug Expert Committee is 80,000 CDN\$ (\~75,000 €) per QALY \[[@pone.0145087.ref063]\], while the threshold of 50,000--100,000 US\$ (\~38,00--75,000 €) per QALY is often used in the US \[[@pone.0145087.ref064],[@pone.0145087.ref065]\]. According to the World Health Organization, an intervention is cost-effective if the cost of intervention per QALY is less than three times the country's annual gross domestic product \[[@pone.0145087.ref066]\]. Even if those thresholds had been used in this review, biologics would not have been deemed cost-effective in most studies. It should be noted that the selection of the willingness-to-pay threshold depends on the relevant context, including the disease burden and the budget of the setting in question.

Most studies used the perspective of the local public health care service or the insurance system while only paying attention to direct costs. Only one study included both direct and indirect costs and reported more favorable ICER when considering both direct and indirect costs in comparison with only direct costs \[[@pone.0145087.ref049]\]. No clear guidelines exist on how productivity losses should be determined causing concern for the validity of the cost estimates. Included cost components and their valuing methods can be difficult to identify based on the publications. Furthermore, productivity costs included in CUA may cause a risk of double-counting as the impact of morbidity is already included in the calculation of QALY \[[@pone.0145087.ref026]\]. The patient´s earnings and leisure activities affect variability on the value of the individual´s time \[[@pone.0145087.ref024]\]. The differences in overall labor costs, health policy, and other health system factors make challenging to compare results between countries. IBDs as chronic diseases are usually diagnosed in early adulthood causing a severe impact on productivity costs. Even though biologics increase the drug costs, they are assumed to improve the health status and to reduce the burden on resources outside the health care system such as absenteeism from work \[[@pone.0145087.ref067]\]. Consequently, it is appropriate to include indirect costs in CUA, but indirect costs should be presented separately from direct costs \[[@pone.0145087.ref024],[@pone.0145087.ref026]\].

When evaluating effectiveness, it is scientifically and ethically important to use the most appropriate alternative treatment as the control group. The comparator with a good efficacy and safety profile should act as the most cost-effective alternative treatment and is usually the intervention most used in clinical practice \[[@pone.0145087.ref032],[@pone.0145087.ref068]\]. However, recommendations on the appropriate comparator vary across countries and depend on the research question \[[@pone.0145087.ref068]\]. A majority of the included studies used the "standard care" or "usual care" as the comparator.

Source of effectiveness data has substantial influence on model results. RCT data was used as effectiveness data in all included CUAs. RCTs give information about efficacy determined in ideal circumstances and cause a risk of overestimating effectiveness in comparison with the treatment in routine healthcare. Therefore, it is plausible to assume that the CUAs using RCTs as a source of effectiveness produce lower ICERs than real-world data. Contrary to that assumption, only one of the included studies derived information from real life studies and resulted in more favorable ICERs when using response rates from real life data rather than from RCTs \[[@pone.0145087.ref054]\]. However, the uncertainty in economic evaluations, especially in modeling studies, can arise from numerous methodological disagreements among analyses. Uncertainty caused by e.g., using multiple data sources and extrapolation beyond the time horizon of the study involving the use of assumptions was tested by sensitivity analysis in most studies.

In most studies, the source of utility data was reported inadequately and considerable variation existed in the instruments used to collect it. Direct elicitation methods (e.g., SG, TTO) were used more frequently than indirect methods (e.g., EQ-5D). With direct methods patients directly score their preferences for health states and make judgments based on their own relative values, while indirect methods are based on the patients' responses to surveys about various aspects of health states \[[@pone.0145087.ref025]\]. The methods of direct elicitation can be complex and time consuming. In most cases, indirect utility estimates were obtained by determining the relationship between values on a disease-specific measure to a generic quality of life measure. This is necessary because of the fact that the generic measures have been applied in few studies, while disease specific measures such as CDAI are commonly used in RCTs. The application of different algorithms for conversions creates a further source of heterogeneity in ICER estimates. Because of the variation in the methods used and in the preferences across individuals, the QALYs may vary widely between the studies and this affects the results of the CUAs.

Based on previous literature, studies with longer time horizon produce more favorable ICERs than studies with shorter time horizons \[[@pone.0145087.ref049],[@pone.0145087.ref053]\]. As biologics improve patients´ health status \[[@pone.0145087.ref067]\], they have potential to yield gain in terms of reductions in hospitalization, surgeries, and incapacity in future. However, the correlation between the length of the time horizon and cost-effectiveness analyses remains unclear in our study. Although the lifetime horizon is appropriate to capture all health effects and costs for chronic diseases, in most modelling studies the time horizon was limited to one year by the availability of the relevant data and to avoid the bias caused by extrapolation to a longer time horizon.

When considering the previously published systematic reviews, only one study used the standardized quality assessment checklist to evaluate the quality of the included CUAs. As far as we know, this is the first systematic review assessing the quality of economic evaluations by three different checklists. Drummond's checklist is recommended to inform appraisal of the methodological quality of full economic evaluations \[[@pone.0145087.ref032],[@pone.0145087.ref069]\]. Drummond's checklist is relevant but not sufficient for modeling studies. Therefore, the modeling's were also assessed using Philip's checklist \[[@pone.0145087.ref032],[@pone.0145087.ref034],[@pone.0145087.ref069]\]. The CHEERS guideline includes additional items relating to the author's disclosure of funding sources and conflicts of interest, sufficient information in article titles, and structured abstracts \[[@pone.0145087.ref033]\]. The CHEERS guideline evaluates the reporting of the study while Drummond's checklist and Philips' checklist are designed to assess the methodological quality of economic evaluations.

The amount of the fulfilled items according to Drummond's checklist and the CHEERS guideline was higher than using Philips' checklist. The reasons may be aims of the checklist and the extensiveness of Philips' checklist including several topics relevant to modeling studies and not considered in Drummond's checklist and the CHEERS guideline. On average, the same CUAs fulfilled the highest amount of the applicable items according to all three checklists. Most of the studies, which fulfilled most criteria of quality assessment checklists, were HTA reports. Almost half of the included CUAs were funded by the pharmaceutical company or authors had received funding from the pharmaceutical companies during the research project \[[@pone.0145087.ref035],[@pone.0145087.ref036],[@pone.0145087.ref042],[@pone.0145087.ref045],[@pone.0145087.ref047]--[@pone.0145087.ref049],[@pone.0145087.ref053],[@pone.0145087.ref055],[@pone.0145087.ref056]\]. Many of the studies funded by the pharmaceutical company produced favorable ICERs \[[@pone.0145087.ref035],[@pone.0145087.ref036],[@pone.0145087.ref048],[@pone.0145087.ref049],[@pone.0145087.ref053],[@pone.0145087.ref056]\]. However, it remained unclear whether the source of funding had an effect on the study results. In addition, the relation between the studies funded by a pharmaceutical company and fulfillment of applicable quality assessment criteria was found to be unclear.

The current review was carefully designed beforehand and documented transparently, improving the validity of the study. The study selection, the data extraction, and the quality assessment were performed by one assessor and any ambiguity was resolved with a second assessor to avoid human mistakes and to improve the reliability of the study. The comprehensive literature search was utilized to minimize bias. The intervention treatments included in the search strategy were limited to biologics that had been granted a marketing authorization by the EMA or FDA for the treatment of IBD. Vedolizumab was not included in the search strategy because its marketing authorization was not granted until the planning and realization of the search strategy was completed.

However, because of a limited amount of available CEAs and some inconsistent results, conclusions remain partially uncertain. Furthermore, variability in data input and heterogeneity in study designs made it challenging to compare studies reliably. To improve the reporting of an individual CEA, it is appropriate to use quality assessment checklists. When using checklists, economic evaluations become more consistent, transparent, and informative. The most important predictors of good cost-effectiveness of the biologics were disease activity, the duration of the biological treatment, and the treatment strategy. Further research is needed to confirm cost-effectiveness in moderate IBD. Future studies should evaluate the cost-effectiveness of all available biologic treatments for IBDs. In addition, CEAs between two different biologics are required to find the most cost-effective treatment strategy for IBD patients.

In conclusion, biologics seem to be cost-effective for the induction treatment of active and severe IBD, but not for the maintenance treatment. Whether there are differences in the cost-effectiveness between biologics remains unclear.
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